Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).

Autor: Michel G; Service d'Hématologie Pédiatrique, Hôpital d'Enfants la Timone, Marseille, France., Baruchel A, Tabone MD, Nelken B, Leblanc T, Thuret I, Bordigoni P, Bergeron C, Esperou-Bourdeau H, Perel Y, Vannier JP, De Lumley L, Dommergues JP, Lamagnère JP, Couillaud G, Auvrignon A, Schaison G, Leverger G
Jazyk: angličtina
Zdroj: Hematology and cell therapy [Hematol Cell Ther] 1996 Apr; Vol. 38 (2), pp. 169-76.
DOI: 10.1007/s00282-996-0169-7
Abstrakt: In the LAME89/91 protocol, children with acute myeloid leukemia (AML) who achieved complete remission (CR) after induction chemotherapy, were treated either with allogeneic bone marrow transplantation (BMT) if they had an HLA-compatible related donor or with chemotherapy including high-dose cytarabine. The objectives of this study were to describe the overall results of this strategy and to compare the two post-remission arms. Two hundred and thirty-one children were enrolled in the protocol. Induction chemotherapy consisted of a combination of cytarabine and mitoxantrone. A CR was achieved in 204 children (88%).
Databáze: MEDLINE
Externí odkaz: